WO2022221962A1 - Stem cells comprising an unrearranged t cell receptor (tcr) gene locus and methods of use thereof - Google Patents
Stem cells comprising an unrearranged t cell receptor (tcr) gene locus and methods of use thereof Download PDFInfo
- Publication number
- WO2022221962A1 WO2022221962A1 PCT/CA2022/050622 CA2022050622W WO2022221962A1 WO 2022221962 A1 WO2022221962 A1 WO 2022221962A1 CA 2022050622 W CA2022050622 W CA 2022050622W WO 2022221962 A1 WO2022221962 A1 WO 2022221962A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- cell
- stem
- progenitor
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Definitions
- the application relates to stem cells that are unable to undergo T cell receptor (TCR) or B cell receptor (BCR) gene rearrangements.
- TCR T cell receptor
- BCR B cell receptor
- the application relates to methods, compositions and kits for use in generating cells of the T cell lineage or B cell lineage comprising an unrearranged TCR gene locus or BCR gene locus, respectively.
- T cells to specifically recognize antigens is accomplished through the expression of specific T cell receptors encoded by the uniquely rearranged genomic loci of the TCRa and b chains. T cell development is predicated on the successful rearrangement of the T cell receptor (TCR) gene loci, which encode for antigen-specific receptors.
- TCR T cell receptor
- V(D)J Recombination Activating Genes (RAG) 1 and 2 are two essential DNA processing enzymes required for the rearrangement of the B cell receptor and T cell receptor gene loci (Schatz at al., 1989; Oettinger et al, 1990).
- RAG 1/2 initiate V(D)J recombination by forming a complex that first recognizes and binds to recombination signal sequences (RSS) found adjacent to each V, D, and J gene segment.
- RSS recombination signal sequences
- the RAG complex Upon formation of a synapse with another RSS, the RAG complex induces a double-strand DNA break, which is repaired by non-homologous end-joining process (Jones and Gellert, 2004; Smith et al, 2019). This ultimately results in the imperfect joining of different V, D, and J gene segments to potentially generate millions of different antigen receptors from a few hundred V(D)J segments.
- the inventors differentiated human pluripotent stem cells with a
- RAG2-KO CRISPR/Cas9-directed deletion of the RAG2 gene
- the disclosure provides a method of generating stem or progenitor cells unable to undergo T cell receptor (TCR) gene rearrangements (TCR), the method comprising:
- the method further comprises (b) isolating cells of the T cell lineage.
- V(D)J recombination is RAG1 and/or RAG2.
- the at least one gene or protein required for V(D)J recombination is selected from the group consisting of Artemis, DNA-dependent protein kinase (DNA-PK), X-ray repair cross-complementing protein 4 (XRCC4), DNA ligase IV, non-homologous end-joining factor 1 (NHEJ1), Paralog of XRCC4 and XLF (PAXX), DNA polymerase l and DNA polymerase m.
- DNA-PK DNA-dependent protein kinase
- XRCC4 X-ray repair cross-complementing protein 4
- NHEJ1 non-homologous end-joining factor 1
- PAXXX Paralog of XRCC4 and XLF
- DNA polymerase l DNA polymerase m.
- the stem cells are pluripotent stem cells.
- the pluripotent stem cells are embryonic stem cells or induced pluripotent stem cells (iPSCs).
- the stem cells or progenitor cells are human cells.
- the cells of the T cell lineage are progenitor T (proT) cells, optionally CD45+CD34+CD7+ progenitor T (proT) cells.
- the cells of the T cell lineage are CD4+CD8+ double positive cells or CD4+CD8+CD3+ double positive cells.
- the cells of the T cell lineage are CD8+CD3+ single positive cells or CD4+CD3+ single positive cells.
- the method further comprises engineering the stem cells or progenitor cells or the cells of the T cell lineage to comprise at least one of a nucleic acid encoding a T cell receptor (TCR), a TCRp chain and a chimeric antigen receptor (CAR).
- TCR T cell receptor
- CAR chimeric antigen receptor
- the stem cells or progenitor cells or the cells of the T cell lineage express the at least one of a T cell receptor (TCR), a TCRp chain and a chimeric antigen receptor (CAR).
- TCR T cell receptor
- CAR chimeric antigen receptor
- the method further comprises engineering the stem cells or progenitor cells or the cells of the T cell lineage to comprise a nucleic acid encoding a TCRp chain.
- the stem cells or progenitor cells or the cells of the T cell lineage that comprise a nucleic acid encoding a TCRp chain do not comprise a nucleic acid that encodes a TCRp chain or a chimeric antigen receptor (CAR).
- the stem cells or progenitor cells or the cells of the T cell lineage express a TCRp chain.
- the stem cells or progenitor cells or the cells of the T cell lineage comprise a nucleic acid encoding a TCRp chain and a nucleic acid encoding a CAR.
- the TCR or CAR confers specificity to an antigen, optionally a tumor-associated antigen, viral antigen or self antigen.
- the disclosure also provides a cell of the T cell lineage, wherein the cell is generated by a method described herein.
- the cell of the T cell lineage is a CD4+CD8+ double positive cell or a CD4+CD8+CD3+ double positive cell.
- the cell is a CD45+CD34+CD7+ progenitor T cell, CD8+CD3+ single positive cell or CD4+CD3+ single positive cell.
- the disclosure also provides a stem or progenitor cell, wherein expression of at least one gene or protein required for V(D)J recombination in the stem cell or progenitor cell is reduced or eliminated compared to a wild-type stem cell or progenitor cell.
- the at least one gene or protein required for V(D)J recombination is RAG1 and/or RAG2.
- the at least one gene or protein required for the at least one gene or protein required for the at least one gene or protein required for the at least one gene or protein required for the at least one gene or protein required for the at least one gene or protein required for the at least one gene or protein required for the at least one gene or protein required for the at least one gene or protein required for the at least one gene or protein required for the at least one gene or protein required for the at least one gene or protein required for the at least one gene or protein required for
- V(D)J recombination is selected from the group consisting of Artemis, DNA-dependent protein kinase (DNA-PK), X-ray repair cross-complementing protein 4 (XRCC4), DNA ligase IV, non-homologous end-joining factor 1 (NHEJ1), Paralog of XRCC4 and XLF (PAXX), DNA polymerase l and DNA polymerase m.
- DNA-PK DNA-dependent protein kinase
- XRCC4 X-ray repair cross-complementing protein 4
- NHEJ1 non-homologous end-joining factor 1
- PAXX Paralog of XRCC4 and XLF
- DNA polymerase l DNA polymerase m.
- the stem or progenitor cell further comprises at least one of a nucleic acid encoding a T cell receptor (TCR), a TCRp chain and a chimeric antigen receptor (CAR).
- TCR T cell receptor
- CAR chimeric antigen receptor
- the stem or progenitor cell further comprises a nucleic acid encoding a TCRp chain.
- the stem or progenitor cell that comprises a nucleic acid encoding a TCRp chain does not comprise a nucleic acid that encodes a TCRp chain or a chimeric antigen receptor (CAR).
- the stem cell is a pluripotent stem cell, optionally an embryonic stem cell or induced pluripotent stem cell (iPSC).
- iPSC induced pluripotent stem cell
- the stem cell or progenitor cell is a human cell.
- the disclosure also provides a use of a stem or progenitor cell as described herein for generating cells of the T cell lineage.
- the disclosure also provides a kit comprising (i) a stem or progenitor cell as described herein and (ii) instructions for use of the stem or progenitor cell as described herein for generating cells of the T cell lineage.
- the disclosure further provides a method of treating a disease or condition in a subject comprising:
- stem cells or progenitor cells are engineered to comprise at least one of a nucleic acid encoding a T cell receptor (TCR) and a chimeric antigen receptor (CAR) that confers specificity to an antigen.
- TCR T cell receptor
- CAR chimeric antigen receptor
- the disclosure also provides a method of treating a disease or condition in a subject comprising: (i) culturing a sample comprising stem cells or progenitor cells, and isolating cells of the T cell lineage wherein expression of at least one gene or protein required for V(D)J recombination in the stem cells or progenitor cells is reduced or eliminated compared to wildtype stem cells or progenitor cells, and
- TCR T cell receptor
- CAR chimeric antigen receptor
- the at least one gene or protein required for V(D)J recombination is RAG1 and/or RAG2.
- the at least one gene or protein required for the at least one gene or protein required for the at least one gene or protein required for the at least one gene or protein required for the at least one gene or protein required for the at least one gene or protein required for the at least one gene or protein required for the at least one gene or protein required for the at least one gene or protein required for the at least one gene or protein required for the at least one gene or protein required for the at least one gene or protein required for the at least one gene or protein required for
- V(D)J recombination is selected from the group consisting of Artemis, DNA-dependent protein kinase (DNA-PK), X-ray repair cross-complementing protein 4 (XRCC4), DNA ligase IV, non-homologous end-joining factor 1 (NHEJ1), Paralog of XRCC4 and XLF (PAXX), DNA polymerase l and DNA polymerase m.
- DNA-PK DNA-dependent protein kinase
- XRCC4 X-ray repair cross-complementing protein 4
- NHEJ1 non-homologous end-joining factor 1
- PAXX Paralog of XRCC4 and XLF
- DNA polymerase l DNA polymerase m.
- the disease is cancer and the antigen is a tumor- associated antigen.
- the disclosure also provides a method of generating stem or progenitor cells unable to undergo T cell receptor (BCR) gene rearrangements, the method comprising:
- the method further comprises (b) isolating cells of the B cell lineage.
- V(D)J recombination is RAG1 and/or RAG2.
- V(D)J recombination is selected from the group consisting of Artemis, DNA-dependent protein kinase (DNA-PK), X-ray repair cross-complementing protein 4 (XRCC4), DNA ligase IV, non-homologous end-joining factor 1 (NHEJ1), Paralog of XRCC4 and XLF (PAXX), DNA polymerase l and DNA polymerase m.
- DNA-PK DNA-dependent protein kinase
- XRCC4 X-ray repair cross-complementing protein 4
- NHEJ1 non-homologous end-joining factor 1
- PAXX Paralog of XRCC4 and XLF
- DNA polymerase l DNA polymerase m.
- the stem cells are pluripotent stem cells, optionally embryonic stem cells or induced pluripotent stem cells (iPSCs).
- the stem cells or progenitor cells are human cells.
- the cells of the B cell lineage are CD20+ or
- the cells of the B cell lineage are Tumor-induced
- TIBs Infiltrating B Cells
- the method further comprises engineering the stem cells or progenitor cells or the cells of the B cell lineage to comprise at least one of a nucleic acid encoding a B cell receptor (BCR), a BCRp chain and a chimeric antigen receptor (CAR).
- BCR B cell receptor
- CAR chimeric antigen receptor
- the stem cells or progenitor cells or the cells of the B cell lineage express the B cell receptor (BCR), the BCRp chain or the chimeric antigen receptor (CAR).
- BCR B cell receptor
- CAR chimeric antigen receptor
- the BCR or CAR confers specificity to an antigen, optionally a tumor-associated antigen, viral antigen or self antigen.
- the disclosure also provides a cell of the B cell lineage, wherein the cell is generated by a method as described herein.
- the cell of the B cell lineage is a CD20+ or CD19+ cell.
- the cell of the B cell lineage is a Tumor-Infiltrating
- TIB B Cell
- the disclosure also provides a use of a stem or progenitor cell as described herein for generating cells of the B cell lineage.
- the disclosure also provides a kit comprising (i) a stem or progenitor cell as described herein and (ii) instructions for use of the stem or progenitor cell as described herein for generating cells of the B cell lineage. [0054] The disclosure also provides a method of treating a disease or condition in a subject comprising:
- stem cells or progenitor cells are engineered to comprise a nucleic acid encoding a B cell receptor (BCR) that confers specificity to an antigen.
- BCR B cell receptor
- the disclosure also provides a method of treating a disease or condition in a subject comprising:
- the at least one gene or protein required for V(D)J recombination is RAG1 and/or RAG2.
- V(D)J recombination is selected from the group consisting of Artemis, DNA-dependent protein kinase (DNA-PK), X-ray repair cross-complementing protein 4 (XRCC4), DNA ligase IV, non-homologous end-joining factor 1 (NHEJ1), Paralog of XRCC4 and XLF (PAXX), DNA polymerase l and DNA polymerase m.
- DNA-PK DNA-dependent protein kinase
- XRCC4 X-ray repair cross-complementing protein 4
- NHEJ1 non-homologous end-joining factor 1
- PAXX Paralog of XRCC4 and XLF
- DNA polymerase l DNA polymerase m.
- the disease is cancer and the antigen is a tumor- associated antigen.
- the antigen is a tumor-associated antigen.
- Fig. 1 shows generation and characterization of RAG2-KO hESC lines.
- Fig. 1A shows Sanger Sequencing of genomic DNA of CRISPR/Cas9- targeted RAG2 of clones 1 and 4. The altered allele is depicted in chromatograph and sequence above it, while alignment of the altered and WT alleles are shown below.
- Fig. 1B shows an immunoblot for RAG2 protein expression of in v/fro-derived T-lineage cells from RAG2-KO clones (1 and 4) and Control WT hESCs, or Control PBMCs obtained from a T- ALL patient. GAPDH serves as a loading control.
- Fig. 1A shows Sanger Sequencing of genomic DNA of CRISPR/Cas9- targeted RAG2 of clones 1 and 4. The altered allele is depicted in chromatograph and sequence above it, while alignment of the altered and WT alleles are shown below.
- Fig. 1B shows an immunoblot for RAG2 protein expression of in
- FIG. 1C shows immunofluorescence of RAG2-KO hESC clones for pluripotency markers. The scale bar corresponds to 100 pm.
- Fig. 1 D shows immunohistochemistry of RAG2-KO hESC clones against ectoderm (neural tissue), mesoderm (cartilage), and endoderm (glandular tissue) lineages of a teratoma formation assay.
- Fig. 2 (A-B) shows T cell development from Control WT and RAG2-
- Fig. 3 shows forced expression of a rearranged TCRp chain in
- FIG. 3A shows a schematic of the experimental approach.
- Fig. 3B shows cell counts of RAG2-KO DPs (clones 1 and 4) retrovirally-transduced with empty vector (dTomato), TCR alpha chain (TRA 1383i), or TCR beta chain (TRB 1383i) per 10,000 input of CD34 + cells.
- Fig. 4 shows TCR gene expression and CD4 + CD8 + signature gene expression.
- Fig. 5A shows a heatmap analysis of specific TCR genes expressed in Control WT DPs but absent in RAG2-K01/4 DPs and TCRp-transduced RAG2-K01/4 DPs.
- Fig. 5 shows transcriptomic analysis of Control WT, RAG2-
- Fig. 6 (A-B) shows an analysis of proliferation and differentiation genes and biological pathways.
- Fig. 6A is a heatmap analysis of differentially expressed genes in DPs from RAG2-K01/4 (KO) and TCRp-transduced RAG2-K01/4 (KOTCRb) cells.
- Fig. 6B shows names of gene ontology biological pathways that involve genes that are differentially up-regulated in Control WT DPs compared to RAG2-KO DPs. Highlighted are biological pathways that are relevant to cell survival and/or proliferation. Within the group of biological pathways that are involved in specific aspects of leukocyte regulation, the specific genes involved are also indicated.
- Fig. 7 (A-B) shows forced expression of TCRaP and TCRy5 chains in RAG2-KO CD4 + CD8 + DPs.
- Fig. 7A shows TCRap- and TCRy8-transduced DPs displayed higher cell numbers after 4 and 10 days of culture compared to dTomato- transduced DPs. From left to right are dTomato, TCRap- and TCRy8.
- Fig. 7B is a flow cytometric analysis of TCR-transduced RAG2-KO DP cells showing expression of the corresponding ab and gd TCRs, respectively, on the cell surface of T-lineage cells.
- the inventors differentiated human pluripotent stem cells with a CRISPR/Cas9-directed deletion of the RAG2 gene (RAG2-KO) and showed that human RAG2-deficient developing T cells progress up to the CD4+CD8+ stage.
- RAG2-KO CD4+CD8+ double positive cells can be engineered to express TCRap and TCRy8 chains and that expression of a rearranged TCRp chain promotes cell survival and/or proliferation of developing human T-cells at the double positive stage.
- the disclosure provides a method of generating stem or progenitor cells unable to undergo T cell receptor (TCR) gene rearrangements, the method comprising:
- the method further comprises (b) isolating cells of the T cell lineage.
- the disclosure also provides a method of generating a cell of the T cell lineage comprising an unrearranged T cell receptor (TCR) gene locus, the method comprising: (a) culturing a sample comprising stem cells or progenitor cells, wherein the expression of at least one gene or protein required for V(D)J recombination in the stem cells or progenitor cells is reduced or eliminated compared to wildtype stem or progenitor cells.
- TCR T cell receptor
- cells of the T cell lineage refers to cells that show at least one phenotypic characteristic of a T cell or a precursor or progenitor thereof that distinguishes the cells from other lymphoid cells, and cells of the erythroid or myeloid lineages.
- phenotypic characteristics can include expression of one or more proteins specific for T lineage commitment on cells or a precursor or progenitor thereof, or a physiological, morphological, functional, or immunological feature specific for a T cell.
- the cells of the T cell lineage are human cells.
- a cell or “the cell” includes a plurality of cells.
- isolated means that a cell has been separated or purified from cellular or biological material found with the cells in their native environment. It thus distinguishes the cells from how they exist in nature.
- the disclosure also provides a method of generating stem or progenitor cells unable to undergo B cell receptor (BCR) gene rearrangements, the method comprising:
- the method further comprises (b) isolating cells of the B cell lineage.
- the disclosure further provides a method of generating a cell of the B cell lineage comprising an unrearranged B cell receptor (BCR) gene locus, the method comprising: (a) culturing a sample comprising stem cells or progenitor cells, and (b) isolating cells of the B cell lineage, wherein the expression of at least one gene or protein required for V(D)J recombination in the stem cells or progenitor cells is reduced or eliminated compared to wildtype stem or progenitor cells.
- BCR B cell receptor
- cells of the B cell lineage refers to cells that show at least one phenotypic characteristic of a B cell or a precursor or progenitor thereof that distinguishes the cells from other lymphoid cells, and cells of the erythroid or myeloid lineages. Such phenotypic characteristics can include expression of one or more proteins specific for B-lineage on cells or a precursor or progenitor thereof, or a physiological, morphological, functional, or immunological feature specific for a B cell.
- the cells of the B cell lineage are CD20+ or CD19+ cells.
- the cells of the B cell lineage are Tumor-Infiltrating B Cells (TIBs).
- the cells of the B cell lineage are human cells.
- Cells of the T cell lineage may be (a) progenitor or precursor cells committed to the T cell lineage (“progenitor T cells” or “proT cells”, as described herein); (b) CD7+ immature T cells; (c) cells that have undergone CD4 or CD8 lineage commitment (e.g.
- CD4+CD8 /0 TCR mi cells (d) characterized by TCR gene rearrangement; (e) precursor thymocytes that are CD4+CD8+ double positive (DP); (f) CD4-CD8+ orCD4+CD8- and optionally TCR h ; (g) CD3+CD90+; (h) single positive (SP) cells that are CD4-CD8+ or CD4+CD8- and TCR' 1 '; (i) TCR-ab * and/or TCR-y6 + ; (j) characterized by expression of any of multiple nb chains (e.g. nb-3, -6, and 17a); or (k) mature and functional or activated T cells which may be characterized as TCR/CD3 h ', CD4-CD8+ or CD4+CD8-.
- TCR gene rearrangement (e) precursor thymocytes that are CD4+CD8+ double positive (DP); (f) CD4-CD8+ orCD4+CD
- a cell of the T cell lineage is a “progenitor T cell’ or
- proT cell The term “progenitor T cell” or “proT cell” as used herein means a T cell that is capable of maturing into a mature T cell or lymphocyte. In one embodiment, the pro T cell is a CD45+CD34+CD7+ proT cell.
- the progenitor T cell is a human progenitor T cell.
- Phenotypes of human progenitor T cells include CD34+CD7+ and CD7+CD5+CD1a-.
- a cell of the T cell lineage is a CD4 and CD8 double positive (DP) cell characterized by a CD4+CD8+ or CD4+CD8+CD3+ phenotype.
- a cell of the T cell lineage is a CD4 or CD8 single positive (SP) cell characterized by a CD4-CD8+, CD4+CD8- or CD4-CD8+CD3+, CD4+CD8-CD3+ phenotype.
- TCR T-cell receptor
- BCR B-cell receptor
- the TCR gene locus can comprise an alpha (a) chain and a beta (b) chain (encoded for example by genes TRA and TRB, respectively), or a gamma and delta (g/d) chains (encoded for example by genes TRG and TRD, respectively).
- TRA and TRB beta chain
- g/d gamma and delta chains
- the term “gene or protein required for V(D)J recombination” refers to a gene of protein that is required for correct rearrangement of the B- or T-cell receptor (BCR or TCR) gene loci.
- the gene or protein required for V(D)J recombination is a lymphocyte specific gene such as RAG1 or RAG2 or TdT.
- the gene or protein required for V(D)J recombination is a member of the non-homologous end joining (NHEJ) pathway for DNA repair.
- NHEJ non-homologous end joining
- the gene or protein required for V(D)J recombination is Artemis, DNA-dependent protein kinase (DNA-PK), X-ray repair crosscomplementing protein 4 (XRCC4), DNA ligase IV, non-homologous end-joining factor 1 (NHEJ1 ; also known as Cernunnos or XRCC4-like factor (XLF)), Paralog of XRCC4 and XLF (PAXX), or the DNA polymerases l and m.
- DNA-PK DNA-dependent protein kinase
- XRCC4 X-ray repair crosscomplementing protein 4
- NHEJ1 non-homologous end-joining factor 1
- XLF Cernunnos or XRCC4-like factor
- PAXX Paralog of XRCC4 and XLF
- V(D)J recombination is RAG1 or RAG2.
- the V(D)J Recombination Activating Genes (RAG) 1 and 2 encode two essential DNA processing enzymes required for the rearrangement of the B- and T-cell receptor (BCR orTCR) gene loci (Schatz at al, 1989; Oettinger et al, 1990).
- BCR orTCR B- and T-cell receptor
- the inventors differentiated human pluripotent stem cells with a CRISPR/Cas9-directed deletion of the RAG2 gene (RAG2- KO) and showed that human RAG2-deficient developing T-cells progress up to the CD4+CD8+ stage.
- a cell of the T cell lineage or B cell lineage may be generated by culturing a sample comprising stem cells or progenitor cells, wherein the expression and/or function of RAG1 and/or RAG2 in the stem cells or progenitor cells is reduced or eliminated compared to wildtype stem cells or progenitor cells.
- RAG1 refers to V(D)J Recombination Activating Protein
- RAG1 is encoded by the RAG1 gene.
- RAG1 includes RAG1 from any species or source. The term also includes sequences that have been modified from any of the known published sequences of RAG1 proteins and genes. RAG1 orthe RAG1 gene may have any of the known published sequences for RAG1 which can be obtained from public sources such as GenBank.
- RAG1 is human RAG1. Examples of human amino acid sequences for RAG1 include GenBank accession no. AAQ13571.1. Examples of human nucleic acid sequences for RAG1 include include GenBank no. NM_001377277.1 (Gene ID: 5896). The aforementioned sequences are incorporated herein by reference.
- RAG2 refers to V(D)J Recombination Activating Protein (RAG) 2, which is encoded by the RAG2 gene.
- RAG2 includes RAG2 from any species or source. The term also includes sequences that have been modified from any of the known published sequences of RAG2 proteins and RAG2 genes. RAG2 or the RAG2 gene may have any of the known published sequences for RAG2 which can be obtained from public sources such as GenBank.
- RAG2 is human RAG2. Examples of the human amino acid sequences for RAG2 include GenBank accession no. AAH22397.1. Examples of human nucleic acid sequences for RAG2 include GenBank accession no. NMJD00536.4 (Gene ID: 5897). The aforementioned sequences are incorporated herein by reference.
- RAG1 expression includes both RAG1 protein expression and RAG1 gene expression.
- RAG2 expression includes both RAG2 protein expression and RAG2 gene expression.
- RAG1 function and “RAG2 function” refers to the biological activity of the RAG1 and RAG2, respectively.
- RAG1 and RAG2 function refers to the biological activity of the RAG1 and RAG2, respectively.
- BCR or TCR B cell receptor and T cell receptor
- V(D)J recombination (for example endogenous expression and/or function of RAG1 and/or RAG2) can be reduced or eliminated using any of a number of methods known in the art.
- Reduced or eliminated expression and/or function of a gene or protein required for V(D)J recombination may be accomplished by mutation of deletion of the corresponding gene sequence.
- Reduced or eliminated expression and/or function of RAG1 or RAG2 may be accomplished for example by mutation or deletion of RAG1 or RAG2 gene sequences.
- RAG1 or RAG2 gene sequences may be mutated or deleted from the genome of pluripotent stem cells using, for example, gene editing methods.
- RNA/DNA guided endonucleases e.g., Clustered Regularly Interspersed Short Palindromic Repeats (CRISPR)/Cas9, Cpf1 , and Argonaute
- CRISPR Clustered Regularly Interspersed Short Palindromic Repeats
- TALE Transcription Activator- Like Effector
- ZFN zinc finger nucleases
- meganucleases can be adapted for use in embodiments of the present disclosure.
- insertions or deletions are made by gene editing to cause a frame shift mutation, leading to gene knock out (i.e., lack of expression of a functional gene product).
- protocols used in the present invention in the context of RAG2 include transfection of an expression vector containing cassettes for GFP, Cas9 endonuclease, a CRISPR chimeric cDNA and a gRNA moiety that targets RAG 2.
- a RAG1 and/or RAG2 inhibitor is used to reduce endogenous RAG1 and/or RAG2 expression and/or function.
- the term “inhibitor” refers to an agent that reduces, decreases or otherwise blocks expression or activity of its target and includes any substance that is capable of inhibiting the expression or activity of the target and includes, without limitation, small molecules, antisense oligonucleotide molecules (antisense nucleic acid molecules), siRNAs or shRNAs, aptamers, proteins, antibodies (and fragments thereof), gene editing agents and other substances directed at the target expression or activity.
- Endogenous RAG1 and/or RAG2 expression and/or function can be reduced transiently or permanently (for example, by introducing gene mutations or deletions into the germline).
- wildtype refers to a cell which has normal (non- modified), endogenous expression levels of a gene or protein required for V(D)J recombination.
- wildtype refers to a cell which has normal (non-modified), endogenous expression levels of RAG1 and/or RAG2 genes or proteins.
- the wildtype cell is optionally a stem or progenitor cell.
- endogenous RAG1 expression and/or function is reduced by at least 5%, 10%, 25%, 50%, 75% or 100% compared to a wild-type cell.
- the cell has no detectable endogenous RAG1 expression and/or function.
- endogenous RAG2 expression and/or function is reduced by at least 5%, 10%, 25%, 50%, 75% or 100% compared to a wild-type cell.
- the cell has no detectable endogenous RAG2 expression and/or function.
- the stem or progenitor cell is a pluripotent stem cell.
- pluripotent stem cell refers to any stem cell having the potential to differentiate into all cell types of a human or animal body, not including extra- embryonic tissues. These stem cells include both embryonic stem cells (ESCs) and induced pluripotent cells (iPSCs).
- ESCs embryonic stem cells
- iPSCs induced pluripotent cells
- the cells suitable for the method of the present invention include stem cells selected from iPSCs and ESCs.
- the pluripotent stem cells are human pluripotent stem cells (hPSCs) and they include human iPSCs (hiPSCs) and human ESCs (hESCs).
- embryonic stem cell or “ESC” as used herein refers to undifferentiated embryonic stem cells that have the ability to integrate into and become part of the germ line of a developing embryo.
- iPSC induced pluripotent stem cell
- somatic cells such as skin or blood cells that have been reprogrammed back into an embryonic-like pluripotent state.
- iPSCs are derived from T cells with a known or unknown TCR specificity (for example, T cells bearing TCRs with specificity against cancer).
- the stem or progenitor cell is a hematopoietic stem or progenitor cell (HSPC).
- the stem or progenitor cell is a CD34 + hematopoietic precursor cell, optionally a CD34 + hemogenic endothelial precursor cell that has been differentiated from an ESC or iPSC, or a CD34 + pre-hematopoietic cell differentiated from an ESC or pluripotent stem cell (PSC).
- PSC pluripotent stem cell
- Various differentiation protocols for obtaining CD34 + cells are known in the art.
- the stem cells or progenitor cells used to generate the cells of the T cell lineage may be obtained from the patient to be treated.
- Stem or progenitor cells may be obtained from any suitable source, including, without limitation, umbilical cord blood, embryos, embryonic tissue, fetal tissue, bone marrow and blood.
- a sample containing stem or progenitor cells is first depleted of non-stem cells or mature cells.
- Negative and positive selection methods known in the art may be used for enrichment of the stem or progenitor cells. For example, cells can be sorted based on cell surface antigens using a fluorescence activated cell sorter, or magnetic beads which bind cells with certain cell surface antigens. Negative selection columns can be used to remove cells expressing lineage specific surface antigens.
- a sample containing stem or progenitor cells is separated into lineage-negative (Lin ) and lineage position (Lin + ) fractions.
- the Lin- fraction can be sorted for CD34 + cells.
- the progenitor cells or stem cells may be cultured under suitable conditions to generate cells of the T cell lineage or B cell lineage. Methods of culturing progenitor cells or stem cells to generate cells of the T cell lineage or B cell lineage are known in the art.
- human pluripotent stem cells may be induced to differentiate as embryoid bodies, then CD34+ cells may be isolated by magnetic-assisted cell-sorting and placed in co-culture with OP9-DL4 cells to induce their differentiation towards the T cell.
- OP9-DL4 cells Such a protocol is described in Kennedy et al. 2012.
- the cells are cultured in the presence of one or more Notch ligands conjugated to a suspension support for a sufficient time to form cells of the T cell lineage.
- the progenitor cells or stem cells may be cultured on plates or in suspension in a bioreactor, optionally a closed or a closed, automated bioreactor.
- a bioreactor optionally a closed or a closed, automated bioreactor.
- Various bioreactors are known in the art and can include batch, fed batch or continuous bioreactors.
- An example of a continuous bioreactor is a continuous stirred-tank reactor model.
- concentrations of progenitor cells or stem cells in the culture are contemplated.
- the concentration of progenitor cells or stem cells in the culture may be anywhere from 1 to millions of cells per ml of media.
- One or more positive cytokines that promote commitment and differentiation of cells of the T cell lineage or B cell lineage may also be added to the culture.
- the cytokines may be human in origin, or may be derived from other species.
- the concentration of a cytokine in a culture is typically about 1-10ng/ml.
- the cytokines used herein are Flt-3-ligand and IL-7 and Stem Cell Factor.
- the cytokines may be used in combination with equal molar or greater amounts of a glycosaminoglycan such as heparin sulfate.
- the cytokines are commercially available or can be produced by recombinant DNA techniques and purified to various degrees. Some of the cytokines may be purified from culture media of cell lines by standard biochemical techniques.
- the additional molecule is a molecule that promotes T cell development (for example, promotes commitment and differentiation of cells of T cell lineage), also referred to herein as a “T cell co stimulatory molecule”.
- T cell co stimulatory molecule the inventors have shown that microbead- conjugated DL4 and VCAM1 cultured with HSPCs accelerated differentiation to the T cell lineage.
- the T cell co-stimulatory molecule is VCAM 1.
- VCAM1 refers to Vascular cell adhesion protein 1 also known as vascular cell adhesion molecule 1 (VCAM1) or cluster of differentiation 106 (CD106), a protein that in humans is encoded by the VCAM1 gene.
- VCAM 1 also includes a mutant or variant of a VCAM1.
- the T cell co-stimulatory molecule is a cytokine or chemokine (Stem Cell Factor, IL-7, CCL25, or CXCR4), Major Histocompatibility Complex (MHC) class I or class II, or co-stimulatory (CD80, CD86) molecule.
- the T cell co-stimulatory molecule comprises at least one protein tag.
- Various protein tags are known in the art and can be used for a number of purposes.
- the T cell co-stimulatory molecule comprises an Fc tag (also known as an Fc-fusion protein).
- the progenitor cells and stem cells may be cultured in culture media comprising conditioned media, non-conditioned media, or embryonic stem cell media.
- suitable conditioned media include IMDM, DMEM, or aMEM, conditioned with embryonic fibroblast cells (e.g. human embryonic fibroblast cells or mouse embryonic fibroblast cells), or equivalent media.
- suitable non-conditioned media include Iscove’s Modified Dulbecco’s Medium (IMDM), DMEM, or aMEM, or equivalent media.
- the culture media may comprise serum (e.g. bovine serum, fetal bovine serum, calf bovine serum, horse serum, human serum, or an artificial serum substitute) or it may be serum free.
- the culture conditions entail culturing the progenitor cells or stem cells for a sufficient period of time so that cells in the preparation form proT cells.
- the culture conditions entail culturing the progenitor cells or stem cells for a sufficient period of time so that cells in the preparation form mature T cells, for example mature SP T cells. It will be appreciated that the cells may be maintained for the appropriate amount of time required to achieve the desired cellular composition.
- the progenitor cells or stem cells are cultured for at least 6, 8, 10, 12, 14, 21 , 28, 35 or 42 days.
- the method further comprises engineering the cells to comprise a nucleic acid encoding a T cell receptor (TCR) or a chimeric antigen receptor (CAR). In another embodiment, the method further comprises engineering the cells to comprise a nucleic acid encoding a T cell receptor beta chain (TCRp).
- TCR T cell receptor
- CAR chimeric antigen receptor
- TCRp T cell receptor beta chain
- the cells may be engineered to comprise a nucleic acid encoding a TCR, CAR and/or TCRp at any time during the differentiation process.
- the stem or progenitor cells comprise a nucleic acid encoding a TCR, CAR and/or TCRp.
- the cells of the T cell lineage comprise a nucleic acid encoding a TCR, CAR and/or TCRp.
- the stem or progenitor cells and/or the cells of the T cell lineage express a TCR, CAR and/or TCRp.
- the stem or progenitor cells or the cells of the T cell lineage comprise a nucleic acid encoding a TCRp alone.
- the stem or progenitor cells or the cells of the T cell lineage comprise a nucleic acid encoding a TCRp and do not comprise a nucleic acid encoding a TCR or CAR.
- the stem or progenitor cells or the cells of the T cell lineage comprise a nucleic acid encoding a TCRp and a nucleic acid encoding a CAR.
- the TCRp directs differentiation while the CAR can provide therapeutic efficacy.
- the method further comprises engineering the cells of the B-cell lineage to express a B cell receptor (BCR), B cell receptor beta chain (BCRp) and/or CAR.
- BCR B cell receptor
- BCRp B cell receptor beta chain
- the cells may be engineered to comprise a nucleic acid encoding a BCR, BCRp and/or CAR at any time during the differentiation process.
- the stem or progenitor cells comprise a nucleic acid encoding a BCR, BCRp and/or CAR.
- the cells of the B cell lineage comprise a nucleic acid encoding a BCR, BCRp and/or CAR.
- the stem or progenitor cells and/or the cells of the B cell lineage express a BCR, BCRp and/or CAR.
- the cells may be engineered by any method known in the art to comprise a nucleic acid encoding a TCR, TCRp, CAR, BCR or BCRp.
- the cells may be transformed with viral or non-viral vectors carrying a TCR, TCRp, CAR, BCR or BCRp.
- viral vectors include, but are not limited to, retroviruses (including lentivirus), adenoviruses and adeno-associated viruses.
- non-viral vectors include, but are not limited to, nude DNA, minicircle DNA vectors, liposomes, polymerizers and molecular conjugates.
- the TCR, BCR or CAR optionally confers specificity to an antigen such as a tumour associated antigen, a viral antigen or a self-antigen.
- a “tumor associated antigen” is an antigen produced by tumor cells. Examples of tumor associated antigens include, but are not limited to, alphafetoprotein (AFP), arcinoembryonic antigen (CEA), CA-125, MUC-1 , Epithelial tumor antigen (ETA), tyrosinase, melanoma-associated antigen (MAGE), WT1 and NYES01.
- a “viral antigen” is an antigen encoded by a viral genome.
- examples of viral antigens include, but are not limited to EBV, CMV, HIV and SARS viral antigens.
- a “self-antigen” is an antigen that is produced by the subject.
- a selfantigen can be a tumor associated antigens.
- a T cell expressing a TCR or CAR conferring specificity to a self-antigen could be used for example to make regulatory T cells that block self-reactive T cells.
- RAG2-deficient (RAG2-KO) human pluripotent stem cell (hPSC) lines were generated RAG2-deficient (RAG2-KO) human pluripotent stem cell (hPSC) lines.
- the disclosure also provides an isolated stem or progenitor cell, wherein expression of at least one gene or protein required forV(D)J recombination, optionally RAG 1 and/or RAG2, in the stem cell or progenitor cell is reduced or eliminated compared to a wildtype stem cell or progenitor cell.
- the stem cell or progenitor cell is human cell.
- the stem cell is a pluripotent stem cell.
- the pluripotent stem cell is an embryonic stem cell or induced pluripotent stem cell (iPSC).
- RAG 1 or RAG2 may be accomplished by any one of a number of methods known in the art.
- the stem cell or progenitor cell comprises a mutated or deleted RAG1 and/or RAG2 gene sequence.
- insertions or deletions in the RAG1 and/or RAG2 gene sequences may cause a frame shift mutation, leading to gene knock out (i.e., lack of expression of a functional gene product).
- endogenous RAG1 expression and/or function is reduced in the stem cell or progenitor cell by at least 5%, 10%, 25%, 50%, 75% or 100% compared to a wild-type cell. In another embodiment, the cell has no detectable endogenous RAG1 expression and/or function. [00136] In another embodiment, endogenous RAG2 expression and/or function is reduced in the stem cell or progenitor cell by at least 5%, 10%, 25%, 50%, 75% or 100% compared to a wild-type cell. In another embodiment, the cell has no detectable endogenous RAG2 expression and/or function.
- the stem cell or progenitor cell further comprises a nucleic acid encoding a TCR, CAR, TCRp, BCR or BCRp.
- stem cell or progenitor cell expresses a TCR, CAR, TCRp, BCR or BCRp.
- the stem or progenitor cell comprises a nucleic acid encoding a TCRp and does not comprise a nucleic acid encoding a TCR or CAR.
- the disclosure further provides cells of the T cell lineage or B cell lineage generated by the methods, systems and kits described herein, or mitotic or differentiated cells that are progeny of the cells.
- the disclosure provides a “progenitor T cell’ or “proT cell” generated by the methods described herein.
- the progenitor T cell is a human progenitor T cell, for example a human progenitor T cell characterized by CD34+CD7+, CD7+CD5+CD1a- or CD45+CD34+CD7+.
- the disclosure also provides a double positive (DP) T-cell characterized by CD4+CD8+ or CD4+CD8+CD3+.
- the disclosure further provides a cell of the T-cell lineage that is a single positive (SP) cell characterized by CD4-CD8+, CD4+CD8- or CD8+CD3+, CD4+CD3+.
- the cells of the T cell lineage further comprise a nucleic acid encoding a TCR, CAR or TCRp. In another embodiment, the cells of the T cell lineage express a TCR, CAR or TCRp.
- the cells of the T cell lineage comprise a nucleic acid encoding a TCRp and does not comprise a nucleic acid encoding a TCR or CAR.
- a cell of the T cell lineage generated by the methods described herein is engineered with a T cell receptor (TCR) or a chimeric antigen receptor (CAR) that confers specificity to an antigen.
- TCR T cell receptor
- CAR chimeric antigen receptor
- the antigen is optionally a tumor associated antigen (TAA), viral antigen or self-antigen.
- T-cells engineered to express a TCR or a CAR to confer specificity to a TAA can be useful for treating conditions such as cancer.
- the cells of the B cell lineage further comprise a nucleic acid encoding a CAR, TCRp, BCR or BCRp. In another embodiment, the cells of the B cell lineage express a CAR, BCR or BCRp.
- a cell of the B cell lineage generated by the methods described herein is engineered with a B cell receptor (BCR) or a chimeric antigen receptor (CAR) that confers specificity to an antigen.
- BCR B cell receptor
- CAR chimeric antigen receptor
- the antigen is optionally a tumor associated antigen (TAA), viral antigen or self-antigen.
- TAA tumor associated antigen
- BCR BCR
- CAR CAR
- the present disclosure provides a pharmaceutical composition
- a pharmaceutical composition comprising isolated stem or progenitor cells or cells of the T cell lineage or B cell lineage generated by the methods described herein and a pharmaceutically acceptable diluent or carrier.
- compositions include, albeit not exclusively, solutions of the proT cells in association with one or more pharmaceutically acceptable vehicles or diluents, and contained in buffered solutions with a suitable pH and iso- osmotic with physiological fluids.
- compositions include, without limitation, lyophilized powders or aqueous or non-aqueous sterile injectable solutions or suspensions, which may further contain antioxidants, buffers, bacteriostats and solutes that render the compositions substantially compatible with the tissues or the blood of an intended recipient.
- Other components that may be present in such compositions include water, surfactants (such as TweenTM), alcohols, polyols, glycerin and vegetable oils, for example.
- Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules, tablets, or concentrated solutions or suspensions.
- compositions may be supplied, for example but not by way of limitation, as a lyophilized powder which is reconstituted with sterile water or saline prior to administration to the patient.
- Pharmaceutical compositions also include cyropreservative solutions.
- cells of the T cell lineage generated by the methods described herein are cryopreserved in appropriate media, for example pharmaceutically acceptable or GMP-grade media and optionally formulated for administration to a subject in need thereof.
- Suitable pharmaceutically acceptable carriers include essentially chemically inert and nontoxic compositions that do not interfere with the effectiveness of the biological activity of the pharmaceutical composition.
- suitable pharmaceutical carriers include, but are not limited to, water, saline solutions, glycerol solutions, ethanol, N-(1(2,3-dioleyloxy)propyl)N,N,N-trimethylammonium chloride (DOTMA), diolesylphosphotidyl-ethanolamine (DOPE), and liposomes.
- DOTMA N-(1(2,3-dioleyloxy)propyl)N,N,N-trimethylammonium chloride
- DOPE diolesylphosphotidyl-ethanolamine
- liposomes Such compositions should contain a therapeutically effective amount of the compound, together with a suitable amount of carrier so as to provide the form for direct administration to the patient.
- compositions can be administered for example, by parenteral, intravenous, subcutaneous, intramuscular, intracranial, intraorbital, ophthalmic, intraventricular, intracapsular, intraspinal, intracisternal, intraperitoneal, intranasal, aerosol or oral administration.
- solutions of the pro-T cells described herein can be prepared in water suitably mixed with a surfactant such as hydroxypropylcellulose.
- Dispersions can also be prepared in glycerol, liquid polyethylene glycols, DMSO and mixtures thereof with or without alcohol, and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms. A person skilled in the art would know how to prepare suitable formulations.
- the cells of the T cell lineage or B cell lineage are present in an amount effective for treating a disease state in a subject need thereof.
- the cell of the T cell lineage is present in an amount effective to enhance hematopoietic progenitor cell engraftment in a subject in need thereof.
- the composition further comprises cells of the T cell lineage, or tissue for transplantation.
- the tissue comprises a thymus.
- the tissue comprises an organ.
- Kits Stem or progenitor cell as described herein may be prepared and packaged in kits for use in generating cells of the T cell lineage or cells of the B cell lineage.
- kits for producing cells of the T cell lineage or cells of the B cell lineage comprising a stem or progenitor cell, wherein the expression of RAG1 and/or RAG2 in the stem cell or progenitor cell is reduced or eliminated compared to wildtype stem cell or progenitor cells.
- the kit further comprises culture media for culturing a sample comprising stem cells or progenitor cells for producing cells of the T cell lineage or cells of the B cell lineage.
- culture media include conditioned media, non-conditioned media, or embryonic stem cell media.
- the culture media may comprise serum (e.g. bovine serum, fetal bovine serum, calf bovine serum, horse serum, human serum, or an artificial serum substitute) or it may be serum free.
- the kit further comprises one or more additional molecules.
- the additional molecule is a molecule that promotes T cell development (for example, promotes commitment and differentiation of cells of T cell lineage), also referred to herein as a “T cell co-stimulatory molecule”.
- the T cell co-stimulatory molecule is VCAM1.
- the media optionally includes one or more cytokines that promote commitment and differentiation of cells of the T cell lineage or cells of the B cell lineage.
- the cytokines may be human in origin, or may be derived from other species.
- the concentration of a cytokine in a culture is typically about 1-10ng/ml.
- the following are representative examples of cytokines that may be employed in the present application: all members of the Flt-3-ligand, and interleukin-7 (IL-7) and Stem Cell Factor.
- the cytokines used herein are Flt-3-ligand and IL-7 and Stem Cell Factor.
- the cytokines may be used in combination with equal molar or greater amounts of a glycosaminoglycan such as heparin sulfate.
- the cytokines are commercially available or can be produced by recombinant DNA techniques and purified to various degrees. Some of the cytokines may be purified from culture media of cell lines by standard biochemical techniques.
- the kit comprises one or more containers for the within-described reagents.
- Printed instructions providing guidance in the use of the reagent(s) may also be included in the kit, in various embodiments.
- the term “instructions” or “instructions for use” typically includes a tangible expression describing the cells, culturing time periods, temperature, media conditions, and the like.
- the instructions describe a method comprising culturing a sample comprising stem cells or progenitor cells.
- T cells and B cells engineered to recognize specific antigens have wide ranging therapeutic applications.
- the disclosure provides method of treating a disease or condition in a subject comprising:
- stem cells or progenitor cells are engineered to comprise at least one of a nucleotide sequence encoding a T cell receptor (TCR), a chimeric antigen receptor (CAR) or a B cell receptor (BCR) that confers specificity to an antigen.
- TCR T cell receptor
- CAR chimeric antigen receptor
- BCR B cell receptor
- the disclosure also provides a method of treating a disease or condition in a subject comprising:
- TCR T cell receptor
- CAR chimeric antigen receptor
- the disclosure also provides a use of cells of the T cell lineage, generated by the methods described herein for treating a disease or condition in a subject, wherein the cells of the T cell lineage are engineered with a T cell receptor (TCR) or a chimeric antigen receptor (CAR) that confer specificity to an antigen.
- TCR T cell receptor
- CAR chimeric antigen receptor
- the disclosure further provides a use of cells of the T cell lineage, generated by the methods described herein for preparation of a medicament for treating a disease or condition in a subject, wherein the cells of the T cell lineage are engineered with a T cell receptor (TCR) or a chimeric antigen receptor (CAR) that confers specificity to an antigen.
- the disclosure also provides cells of the T cell lineage, generated by the methods described herein for use in treating a disease or condition in a subject, wherein the cells of the T cell lineage are engineered with a T cell receptor (TCR) or a chimeric antigen receptor (CAR) that confers specificity to an antigen.
- TCR T cell receptor
- CAR chimeric antigen receptor
- the disclosure also provides a method of treating a disease or condition in a subject comprising:
- the cells of the B cell lineage are engineered with at least one B cell receptor (TCR) to confer specificity to an antigen.
- TCR B cell receptor
- the disclosure also provides a use of cells of the B cell lineage, generated by the methods described herein for treating a disease or condition in a subject, wherein the cells of the B cell lineage are engineered with a B cell receptor (BCR) or CAR that confers specificity to an antigen.
- BCR B cell receptor
- the disclosure further provides a use of cells of the B cell lineage, generated by the methods described herein for preparation of a medicament for treating a disease or condition in a subject, wherein the cells of the B cell lineage are engineered with a B cell receptor (BCR) or CAR that confers specificity to an antigen.
- the disclosure also provides cells of the B cell lineage, generated by the methods described herein for use in treating a disease or condition in a subject, wherein the cells of the B cell lineage are engineered with a B cell receptor (BCR) or CAR that confers specificity to an antigen.
- BCR B cell receptor
- the antigen is optionally a tumor associated antigen (TAA), a viral antigen or a self-antigen.
- TAA tumor associated antigen
- the antigen is a TAA and the disease is cancer.
- the phrase "effective amount” or “therapeutically effective amount” means an amount effective, at dosages and for periods of time necessary to achieve the desired result. Effective amounts may vary according to factors such as the disease state, age, sex, weight of the subject. The amount of a given cell preparation that will correspond to such an amount will vary depending upon various factors. Such as the pharmaceutical formulation, the route of administration, the type of disease or disorder, the identity of the subject or host being treated, and the like, but can nevertheless be routinely determined by one skilled in the art. An “effective amount” will preferably be an amount effective for the cell of the T cell lineage to engraft the subject being treated.
- treating means an approach for obtaining beneficial or desired results, including clinical results.
- beneficial or desired clinical results can include, but are not limited to, alleviation or amelioration of one or more symptoms or conditions, diminishment of extent of disease, stabilized (i.e. not worsening) state of disease, preventing spread of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, diminishment of the reoccurrence of disease, and remission (whether partial or total), whether detectable or undetectable.
- Treating and “treatment” can also mean prolonging survival as compared to expected survival if not receiving treatment.
- Treatment as used herein also includes prophylactic treatment.
- subject as used herein means any member of the animal kingdom and is preferably a human.
- hESC Maintenance Human ESCs (H1 ; WiCell Research Institute, Madison, Wl) were maintained and expanded on plates coated with Matrigel (Corning, NY, USA) in TeSR-E8 medium (STEMCELL Technologies, Vancouver, Canada). Cells were passaged by non-enzymatic dissociation using 0.5 mM EDTA.
- cellular lysates were prepared by incubating the cells in lysis buffer (50 mM Tris-HCI, pH7.5, 150 mM NaCI, 0.5% NP-40, 2 mM EDTA) containing protease inhibitor cocktail (Roche) for 20 min at 4°C, followed by centrifugation at 14000*g for 15 min at 4°C. Proteins were separated by SDS-PAGE, transferred onto PVDF membrane (Millipore, Louis, MO) and probed with anti-RAG2 antibody (Abeam - Ab95955; 1 :1000 dilution) overnight at 4°C followed by incubation with secondary antibody.
- lysis buffer 50 mM Tris-HCI, pH7.5, 150 mM NaCI, 0.5% NP-40, 2 mM EDTA
- protease inhibitor cocktail Roche
- the anti-RAG2 antibody used was a rabbit polyclonal made against a recombinant fragment corresponding to amino acids 271-519 of human RAG2 (Abeam), which are well beyond the gRNA targeting site. Immunoreactive bands were visualized using western blotting Luminol reagent (Thermo). PBMCs from a T-ALL patient were used as positive control (Bories et al, 1991).
- embryoid bodies were harvested and dissociated into single-cells using Collagenase type IV and trypsin-EDTA as previously described (Kennedy et al, 2012), and positively selected using a MACS column (Miltenyi Biotec) with anti-CD34 PE-conjugated antibody (BD Biosciences) and anti-PE microbeads.
- MACS column Miltenyi Biotec
- anti-CD34 PE-conjugated antibody BD Biosciences
- anti-PE microbeads anti-PE microbeads.
- the cell yield and purity of the positive selection was assessed pre- and post- MACS by flow cytometry.
- OP9-DL4-7FS Co-Culture and Differentiation.
- OP9-DL4 cells expressing hlL-7, hFLT3-L, and hSCF (7FS) were generated and grown in a-MEM containing 10-20% FBS (Gibco), 1% Pen-Strep (Life Technologies), and phospho- ascorbic acid (Sigma-Aldrich) at 37°C, 5% CO2.
- FBS Gibco
- Pen-Strep Life Technologies
- phospho- ascorbic acid Sigma-Aldrich
- MACS-purified CD34 + cells were counted and seeded at a density of 5-20 x10 4 cells per 6-well plate, and differentiated by coculture with OP9-DL4-7FS cells in OP9 medium at 37°C, 5% CO2, and cell were passaged and co-cultured with fresh OP9-DL4-7FS cells every ⁇ 5 days.
- Retroviral Transduction PG13 cell lines stably expressing empty vector dTomato, TCRa-dTomato, or TCRp-dTomato were grown towards 70% confluency, at which point the media was switched to a-MEM with 15% FBS and 1% Pen-Strep to condition the supernatant for 48 h before transducing OP9-DL4-7FS/T-cell cultures.
- RNA-Seq Analysis of Control and RAG2-KO in vitro Derived CD4 + CD8 + cells were resuspended in flow cytometry buffer containing DAPI, data was collected using LSR Fortessa flow cytometer (BD Biosciences) and analyzed using FlowJo version 9.7.6. For intracellular staining, cells were fixed and permeabilized using Fixation/Permeabilization kit with GolgiPlugTM (BD Biosciences) as per manufacturer’s instructions. [00187] RNA-Seq Analysis of Control and RAG2-KO in vitro Derived CD4 + CD8 + cells.
- FIG. 1A CRISPR-Cas9 gene editing was used to target exon 3 of the RAG2 gene.
- hPSCs were transfected with a plasmid encoding the RAG2-targeting guide RNA, the Cas9 enzyme, and green fluorescent protein (GFP).
- GFP + hPSCs were single-cell sorted and cultured. After expanding individual clones, two clones were identified that contained unique insertion-deletions with bi-allelic mutations (KO-1 and KO-4) (Fig. 1A).
- Western blot analysis was performed, which confirmed the absence of detectable RAG2 protein in both KO-1 and -4 derived T-lineage cells (Fig. 1B).
- CD34 expression was analyzed after 8 days of embryoid- body differentiation cultures (Kennedy et al, 2012).
- Control WT, RAG2-KO-1 and -4 hPSCs gave rise to similar frequencies of hemogenic endothelial CD34 + cells, which could be further enriched by magnetic-assisted cell sorting (MACS) (Fig. 1E).
- MCS magnetic-assisted cell sorting
- T-cell development from RAG2-KO hPSCs CD34 + hemogenic endothelial cells were MACS-enriched and cultured with OP9-DL4 cells, expressing human IL-7, FLT3-ligand and stem cell factor (7FS), to induce T-cell differentiation.
- Control WT, RAG2-KO-1 and -4 cells proceeded along the T-cell lineage, as marked by expression of both CD7 and CD5 (Fig. 2A). All three groups reached the CD4 + intermediate single positive (ISP) stage by day 15 and displayed intracellular CD3 expression by day 20 (Fig. 2A).
- ISP intermediate single positive
- RAG2-KO hPSC-derived CD34 + cells were cultured on OP9-DL4-7FS cells for 24 days, and DP cells were retrovirally-transduced with an empty vector (dTomato), a rearranged TCRa chain (TRA 1383 ⁇ ), or a rearranged TCRp chain (TRB 1383i) (Fig. 3A).
- Transduced RAG-KO cells were sorted for CD7 + CD5 + CD4 + CD8 + DP cells, and placed back on OP9-DL4-7FS cells for an additional 10 days to assess for cell survival and expansion (Fig. 3A). Both dTomato- and TCRa-transduced DPs showed similar cell numbers after 10 days of culture (Fig. 3B).
- TCRp-transduced DPs displayed significantly higher cell numbers after 10 days of culture compared to dTomato- and TCRa-transduced DPs (Fig. 3B). Without being bound by theory, this suggests that, in contrast to a TCRa chain, expression of a rearranged TCRp chain promotes cell survival and/or proliferation of developing human T-cells at the DP stage.
- Control WT, RAG2-KO, and RAG2-KO TCRp-transduced CD4 + CD8 + DP cells were sorted for RNA sequencing (RNA-Seq) analysis.
- Control WT DP cells expressed a large set of TCRa, TCRp, TCRy, and TCR6 genes that were absent in RAG2-KO control-transduced and RAG-KO TCRp- transduced DP cells, with the notable exception of some TCR genes, including the 1383i TCRp used in the transduction and a few TCRa genes, likely the result of germline transcripts induced by the b-selection signals, as seen in mice (Villey et al, 1997) (Table 1, and Fig. 4A).
- RAG2-KO hPSCs were generated to assess the role of TCRp during human T-cell development.
- Lack of RAG 1/2 in mice results in a definitive block at the CD44 CD25 + DN3 stage, as it is well documented that RAG1/2-mediated TCRp rearrangement controls the transition from the DN3 to the CD44 CD25- DN4 and DP stages (von Boehmer et al, 1999; Michie and Zuniga-Pflucker, 2002).
- mice expression of a preTCR in DN3 cells leads to expression of Bmi-1 , which represses the expression of the cell cycle inhibitor Cdkn2a. Repression of Cdkn2a is required for preTCR-induced cell proliferation and the DN3-DP transition (Miyazaki et al, 2008).
- this study reveals the unexpected timing required for TCRb-mediated b-selection in developing human T-cells.
- RAG2-KO hPSC-derived CD34 + cells were cultured on OP9-DL4-7FS cells for 21 days, and DP cells were retrovirally-transduced with an empty vector (dTomato), rearranged TCRa ⁇ chains (1383i-TCR) (Roszkowski et al., 2003), or rearranged TCRy8 chains (3C2-TCR) (Benveniste et al., 2018) (Fig. 7).
- Transduced RAG-KO cells were sorted for CD7 + CD5 + CD4 + CD8 + DP cells, and placed back on OP9- DL4-7FS cells for an additional 4 and 10 days to assess for cell survival and expansion (Fig. 7A).
- TCRa ⁇ - and TCRy8-transduced DPs displayed higher cell numbers after 4 and 10 days of culture compared to dTomato-transduced DPs (Fig. 7A), with TORab- transduced cells showing a much higher fold expansion than TCRy5-transduced cells, and akin to what was seen with TCRb-transduced DP cells (Fig. 3).
- TCR-transduced RAG2-KO DP cells showed the expression of the corresponding ab and gd TCRs, respectively, on the cell surface of T-lineage cells (Fig. 7B).
- CRISPR-Cas9 gene editing is used to target each of the following genes: Artemis, DNA-dependent protein kinase (DNA-PK), X-ray repair cross-complementing protein 4 (XRCC4), DNA ligase IV, non-homologous end-joining factor 1 (NHEJ1 ; also known as Cernunnos orXRCC4-like factor (XLF)), Paralog of XRCC4 and XLF (PAXX), DNA polymerase l and DNA polymerase m.
- DNA-PK DNA-dependent protein kinase
- XRCC4 X-ray repair cross-complementing protein 4
- NHEJ1 non-homologous end-joining factor 1
- XLF Cernunnos orXRCC4-like factor
- PAXX Paralog of XRCC4 and XLF
- DNA polymerase l DNA polymerase m.
- hPSCs are transfected with a plasmid encoding the gene targeting guide RNA, the Cas9 enzyme, and green fluorescent protein (GFP).
- GFP + hPSCs are single-cell sorted and cultured.
- KO hPSCs are injected into immunodeficient mice, and histological analysis reveals KO teratoma formation with all three germ layers, indicating that KO hPSCs retain key features of pluripotency.
- CD34 expression is analyzed after 8 days of embryoid-body differentiation cultures (Kennedy et al, 2012). Control WT and KO hPSCs give rise to similar frequencies of hemogenic endothelial CD34 + cells.
- T-cell development from KO hPSCs CD34 + hemogenic endothelial cells are MACS-enriched and cultured with OP9-DL4 cells, expressing human IL-7, FLT3-ligand and stem cell factor (7FS), to induce T-cell differentiation. After 10 days of culture, Control WT and KO cells proceed along the T-cell lineage, as marked by expression of both CD7 and CD5. All three groups reach the CD4 + intermediate single positive (ISP) stage by day 15 and display intracellular CD3 expression by day 20. After 24 days of culture, the majority of cells from Control WT and KO groups are CD7 + CD5 + By 29-34 days of culture, Control WT and KO cells all reach the CD4 + CD8 + DP stage.
- ISP intermediate single positive
- KO hPSC- derived CD34 + cells are cultured on OP9-DL4-7FS cells for 24 days, and DP cells are retrovirally-transduced with an empty vector (dTomato), a rearranged TCRa chain (TRA 1383i), or a rearranged TCRp chain (TRB 1383i).
- Transduced KO cells are sorted for CD7 + CD5 + CD4 + CD8 + DP cells, and placed back on OP9-DL4-7FS cells for an additional 10 days to assess for cell survival and expansion.
- Both dTomato- and TCRa-transduced DPs show similar cell numbers after 10 days of culture. However, TCRp-transduced DPs display significantly higher cell numbers after 10 days of culture compared to dTomato- and TCRa-transduced DPs.
- KO SP T cells Generation of KO SP T cells.
- KO hPSCs engineered with one or more of a rearranged TCRpchain (TRB 1383i), a CAR or a TCR are differentiated into CD34+ cells and subsequently CD4+CD8+ DP cells as above or in stromal cell-free conditions (see for example WO2019157597A1 , the contents of which are incorporated by reference in their entirety).
- Generated CD4+CD8+ DP cells are further differentiated into CD4-CD8+ SP and/or CD8-CD4+ SP T cells.
- KO DP cells engineered with TCRp successfully progress to SP T cells in comparison with KO-only cells.
- Table 2 List of genes significantly up-regulated (p ⁇ 0.05) in Control WT DPs compared to RAG2-KO-4 DPs, or vice versa, as indicated: (NA: non-assigned TCR gene names).
- Table 3 List of genes significantly up-regulated (p ⁇ 0.05) in thymus DNs (CD34+CD7+CD1a+CD4-CD8-) compared to thymus DPs (CD4+CD8+), or vice versa from Casero et al., 2015 (18), as indicated: (NA: non-assigned TCR gene names).
- V(D)J recombination activating gene RAG-1. Cell 59: 1035-1048.
- Beta-selection is associated with the onset of CD8beta chain expression on
- CD4(+)CD8alphaalpha(+) pre-T cells during human intrathymic development CD4(+)CD8alphaalpha(+) pre-T cells during human intrathymic development.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023564480A JP2024515697A (ja) | 2021-04-23 | 2022-04-22 | 再構成されていないt細胞受容体(tcr)遺伝子座を含む幹細胞及びその使用方法 |
| CN202280042484.9A CN117480249A (zh) | 2021-04-23 | 2022-04-22 | 包含未重排的t细胞受体(tcr)基因座的干细胞及其使用方法 |
| EP22790648.4A EP4326856A4 (en) | 2021-04-23 | 2022-04-22 | STEM CELLS COMPRISING AN UNREARRANGED T CELL RECEPTOR (TCR) GENE LOCUS AND METHODS OF USE THEREOF |
| CA3216417A CA3216417A1 (en) | 2021-04-23 | 2022-04-22 | Stem cells comprising an unrearranged t cell receptor (tcr) gene locus and methods of use thereof |
| US18/287,970 US20240209314A1 (en) | 2021-04-23 | 2022-04-22 | T cells comprising an unrearranged t cell receptor (tcr) gene locus and methods of use thereof |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163178990P | 2021-04-23 | 2021-04-23 | |
| US63/178,990 | 2021-04-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2022221962A1 true WO2022221962A1 (en) | 2022-10-27 |
Family
ID=83723544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CA2022/050622 Ceased WO2022221962A1 (en) | 2021-04-23 | 2022-04-22 | Stem cells comprising an unrearranged t cell receptor (tcr) gene locus and methods of use thereof |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240209314A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4326856A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2024515697A (cg-RX-API-DMAC10.html) |
| CN (1) | CN117480249A (cg-RX-API-DMAC10.html) |
| CA (1) | CA3216417A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2022221962A1 (cg-RX-API-DMAC10.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112041431A (zh) * | 2018-02-14 | 2020-12-04 | 桑尼布鲁克研究所 | 产生t细胞谱系细胞的方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015290554A1 (en) * | 2014-07-18 | 2017-03-09 | Kyoto University | Method for inducing T cells for cell-based immunotherapy from pluripotent stem cells |
| WO2018183823A1 (en) * | 2017-03-31 | 2018-10-04 | Hera Testing Laboratories, Inc. | Novel immunodeficient rat for modeling human cancer |
-
2022
- 2022-04-22 EP EP22790648.4A patent/EP4326856A4/en active Pending
- 2022-04-22 US US18/287,970 patent/US20240209314A1/en active Pending
- 2022-04-22 CN CN202280042484.9A patent/CN117480249A/zh active Pending
- 2022-04-22 JP JP2023564480A patent/JP2024515697A/ja active Pending
- 2022-04-22 WO PCT/CA2022/050622 patent/WO2022221962A1/en not_active Ceased
- 2022-04-22 CA CA3216417A patent/CA3216417A1/en active Pending
Non-Patent Citations (7)
| Title |
|---|
| CHEN EDWARD L. Y., BRAUER PATRICK M., MARTINEZ ELISA C., HUANG XIAOTIAN, YU NING, ANDERSON MICHELE K., LI YANG, ZÚÑIGA-PFLÜCKER JU: "Cutting Edge: TCR-β Selection Is Required at the CD4 + CD8 + Stage of Human T Cell Development", THE JOURNAL OF IMMUNOLOGY, WILLIAMS & WILKINS CO., US, vol. 206, no. 10, 15 May 2021 (2021-05-15), US , pages 2271 - 2276, XP093003080, ISSN: 0022-1767, DOI: 10.4049/jimmunol.2100141 * |
| KIM JOO-IL, PARK JIN-SUNG, KIM HANNA, RYU SOO-KYUNG, KWAK JINA, KWON EUNA, YUN JUN-WON, NAM KI-TAEK, LEE HAN-WOONG, KANG BYEONG-CH: "CRISPR/Cas9-mediated knockout of Rag-2 causes systemic lymphopenia with hypoplastic lymphoid organs in FVB mice", LABORATORY ANIMAL RESEARCH, vol. 34, no. 4, 1 January 2018 (2018-01-01), pages 166, XP093003078, ISSN: 1738-6055, DOI: 10.5625/lar.2018.34.4.166 * |
| LEE JAE HOON; PARK JONG-HYUNG; NAM TAE-WOOK; SEO SUN-MIN; KIM JUN-YOUNG; LEE HAN-KYUL; HAN JONG HYUN; PARK SONG YI; CHOI YANG-KYU;: "Differences between immunodeficient mice generated by classical gene targeting and CRISPR/Cas9-mediated gene knockout", TRANSGENIC RESEARCH, SPRINGER NETHERLANDS, NL, vol. 27, no. 3, 28 March 2018 (2018-03-28), NL , pages 241 - 251, XP036518456, ISSN: 0962-8819, DOI: 10.1007/s11248-018-0069-y * |
| MINAGAWA ATSUTAKA; YOSHIKAWA TOSHIAKI; YASUKAWA MASAKI; HOTTA AKITSU; KUNITOMO MIHOKO; IRIGUCHI SHOICHI; TAKIGUCHI MAIKO; KASSAI Y: "Enhancing T Cell Receptor Stability in Rejuvenated iPSC-Derived T Cells Improves Their Use in Cancer Immunotherapy", CELL STEM CELL, ELSEVIER, CELL PRESS, AMSTERDAM, NL, vol. 23, no. 6, 6 December 2018 (2018-12-06), AMSTERDAM, NL , pages 850, XP085555973, ISSN: 1934-5909, DOI: 10.1016/j.stem.2018.10.005 * |
| See also references of EP4326856A4 * |
| SHINKAI, Y. ; RATHBUN, 0. ; LAM, K.-P. ; OLTZ, E.M. ; STEWART, V. ; MENDELSOHN, M. ; CHARRON, J. ; DATTA, M. ; YOUNG, F. ; STALL, : "RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement", CELL, ELSEVIER, AMSTERDAM NL, vol. 68, no. 5, 6 March 1992 (1992-03-06), Amsterdam NL , pages 855 - 867, XP024244599, ISSN: 0092-8674, DOI: 10.1016/0092-8674(92)90029-C * |
| ZHAO QIJIE, JIANG YU, XIANG SHIXIN, KABOLI PARHAM JABBARZADEH, SHEN JING, ZHAO YUESHUI, WU XU, DU FUKUAN, LI MINGXING, CHO CHI HIN: "Engineered TCR-T Cell Immunotherapy in Anticancer Precision Medicine: Pros and Cons", FRONTIERS IN IMMUNOLOGY, vol. 12, XP093003084, DOI: 10.3389/fimmu.2021.658753 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112041431A (zh) * | 2018-02-14 | 2020-12-04 | 桑尼布鲁克研究所 | 产生t细胞谱系细胞的方法 |
| US12467034B2 (en) | 2018-02-14 | 2025-11-11 | Sunnybrook Research Institute | Method for generating cells of the T cell lineage |
Also Published As
| Publication number | Publication date |
|---|---|
| US20240209314A1 (en) | 2024-06-27 |
| CA3216417A1 (en) | 2022-10-27 |
| JP2024515697A (ja) | 2024-04-10 |
| EP4326856A1 (en) | 2024-02-28 |
| CN117480249A (zh) | 2024-01-30 |
| EP4326856A4 (en) | 2025-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3612557B1 (en) | Antigen-specific immune effector cells | |
| KR102598351B1 (ko) | 만능 줄기 세포를 hla 동형 접합 면역 세포로 직접 분화시키기 위한 방법 | |
| AU2023202753A1 (en) | Genomic engineering of pluripotent cells | |
| US20250263670A1 (en) | Cellular reprogramming using temporal and transient plasmid vector expression system | |
| CN113906133A (zh) | 工程改造的iPSC和免疫效应细胞中的CD3重建 | |
| JP2023507118A (ja) | 治療のための操作された細胞 | |
| KR20180063333A (ko) | 면역 세포로의 만능 줄기 세포의 지정된 분화 방법 | |
| EP4326856A1 (en) | Stem cells comprising an unrearranged t cell receptor (tcr) gene locus and methods of use thereof | |
| JP2024526237A (ja) | 同種異系養子細胞療法のための保護されたエフェクター細胞及びその使用 | |
| US20250368955A1 (en) | B cell lineages derived from pluripotent cells | |
| US20250332260A1 (en) | Immune compatible cells for allogeneic cell therapies to cover global, ethnic, or disease-specific populations | |
| US20080112933A1 (en) | Methods and Compositions for Increasing Stem Cell Homing Using Gas Activators | |
| HK40085019A (en) | Genomic engineering of pluripotent cells | |
| HK40073230A (en) | Enhanced chimeric antigen receptor for immune effector cell engineering and use thereof | |
| HK40069004A (en) | Enhanced chimeric antigen receptor for immune effector cell engineering and use thereof | |
| HK40020701A (en) | Cellular reprogramming using temporal and transient plasmid vector expression system | |
| HK1258739B (en) | Genomic engineering of pluripotent cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22790648 Country of ref document: EP Kind code of ref document: A1 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2023564480 Country of ref document: JP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 18287970 Country of ref document: US Ref document number: 3216417 Country of ref document: CA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2022790648 Country of ref document: EP |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| ENP | Entry into the national phase |
Ref document number: 2022790648 Country of ref document: EP Effective date: 20231123 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 202280042484.9 Country of ref document: CN |